Filing Flows › Twist Bioscience (TWST) › Q3 FY26 › vs Q3 FY25
Twist Bioscience (TWST) Q3 FY26 vs Q3 FY25 (year over year)
Twist Bioscience's revenue rose $22.3M (+23%) from $96.1M in Q3 FY25 to $118M in Q3 FY26. The biggest changes: DNA synthesis and protein solutions +$15.8M (+39%); NGS applications +$6.5M (+12%).
Twist Bioscience, Q3 FY26: revenue $118M (+23% year over year), operating margin -30.6%, net loss $35.1M, operating cash flow $1.1M. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| NGS applications | $61.8M | $55.3M | $6.5M | +12% |
| DNA synthesis and protein solutions | $56.6M | $40.8M | $15.8M | +39% |
| Revenue | $118M | $96.1M | $22.3M | +23% |
| Other income, net | $1.5M | $50.7M | −$49.2M | -97% |
| Net loss | $35.1M | −$20.4M | $55.4M | — |
| Costs & expenses | $155M | $147M | $8.2M | +6% |
| Operating costs | $155M | $126M | $28.5M | +23% |
| Income tax | $311K | $191K | $120K | +63% |
| Cost of revenue | $55.9M | $44.8M | $11.2M | +25% |
| Research & development | $18.0M | $18.0M | −$22K | -0.1% |
| SG&A | $80.7M | $63.4M | $17.3M | +27% |
| Operating cash sources | $36.2M | −$21.8M | $58.0M | — |
| Depreciation & amortization | $6.8M | $6.1M | $713K | +12% |
| Share-based compensation | $18.2M | $16.1M | $2.1M | +13% |
| Working capital & other | $11.2M | −$43.9M | $55.1M | — |
| Net loss absorbed | $35.1M | −$20.4M | $55.4M | — |
| Operating cash flow | $1.1M | −$1.4M | $2.5M | — |
| Capital expenditures | $9.8M | $9.2M | $598K | +7% |
| Negative free cash flow (OCF − capex) | $8.6M | $10.6M | −$1.9M | -18% |
Questions
How much did Twist Bioscience's revenue grow year over year in Q3 FY26?
Twist Bioscience's revenue rose $22.3M (+23%) from $96.1M in Q3 FY25 to $118M in Q3 FY26.
What drove Twist Bioscience's revenue change in Q3 FY26?
DNA synthesis and protein solutions +$15.8M (+39%); NGS applications +$6.5M (+12%).